Table 1 Characteristics of patients included in the study
Age (years), mean (SD) | 61.4 (10.8) |
Male/Women (n) | 19/8 |
BMI (kg/m²), mean (SD) | 24.6 (3.2) |
Body weight (kg), mean (SD) | 64.9 (8.9) |
HbA1c (%), mean (SD) | 7.4 (1.0) |
Fasting plasma glucose levels (mg/dL), mean (SD) | 145.8 (35.9) |
Duration of diabetes (years), mean (SD) | 8.8 (7.6) |
Alcohol consumption, % | 36.0 |
Smoking, % | 44.0 |
eGFR (mL/min/1.73 m2), mean (SD) | 82.7 (21.1) |
ACR (mg/gCr), mean (SD) | 34.1 (54.6) |
Systolic blood pressure (mmHg), mean (SD) | 129.8 (8.0) |
Diastolic blood pressure (mmHg), mean (SD) | 79.7 (7.3) |
LDLC(mg/dL), mean (SD) | 120.5 (31.4) |
HDLC (mg/dL) mean (SD) | 53.2 (14.0) |
TG (mg/dL), mean (SD) | 134.3 (49.4) |
Retinopathy, % | 14.8 |
Neuropathy, % | 31.8 |
Nephropathy, % | 29.6 |
Cardiovascular diseases, % | 3.7 |
Oral hypoglycemic agent | N (%)* |
|---|---|
α-glucosidase inhibitors | 0 |
Sulfonylureas | 8 (29.6) |
Biguanides | 16 (59.2) |
Glinide | 0 |
SGLT2 inhibitors | 0 |
Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers | 9 (33.3) |
Statin | 10 (37.0) |